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Patients with head and neck cancer represent 11% of the malignant
tumours diagnosed in French males (Ménégoz et al, 1998). While
most small tumours can be cured, a majority of the tumours are
advanced and despite progress in surgery and radiotherapy, the
prognosis remains poor. In the past years, systemic chemotherapy
has been used in an attempt to improve the results of loco-regional
treatment. Clinical trials have shown a high response rate with a
combination of Cisplatinum (CDDP) and 5 Fluoro-Uracil (5FU) in
head and neck carcinoma sites (Decker et al, 1983; Weaver et al,
1985; Calais et al, 1988). 
In 1986, we decided to investigate the efficiency of neoadjuvant
chemotherapy in a single tumour site: the oropharynx with sur-
vival as the main study end-point, and event-free survival as a
secondary endpoint. 
MATERIALS AND METHODS 
All patients with a biopsy-proven squamous cell carcinoma of all
sites of the oropharynx except for the posterior wall and the anterior
surface of epiglottis, classified as T2 to T4, N0to N2b, and M0(UICC-
AJC, 1986) were eligible if curative treatment, either radiotherapy or
surgery, was considered feasible. Patients older than 69, younger 
than 18 or in whom chemotherapy was contraindicated, or who had
previously been treated, or with multiple tumours were excluded.
Patients were randomized by telephone to receive either neoadjuvant
chemotherapy or no chemotherapy. Randomization was stratified on
the centre and on the local treatment which was either surgery
followed or not by radiotherapy, or radiotherapy alone. 
The treatment planned consisted, in the study arm, of 3 chemo-
therapy cycles followed, if possible, by surgery and systematic
radiotherapy, or if surgery was impossible by radiotherapy alone.
Post-randomization consent was obtained from each patient in
accordance with the law in use in France at the time of the trial. 
A total of 318 patients treated in 6 centres were included in the
trial between 1986 and 1992. 
Chemotherapy 
Chemotherapy consisted of Cisplatin (100 mg/m2) given in a 
1-hour i.v. infusion on day 1 followed by a 24-hour i.v. infusion of
fluorouracil (1000 mg/m2/day) for 5 days. This treatment was
repeated on day 22 unless tumour progression exceeded 25%, 
and repeated on day 43 only if tumour regression had been
observed. 2–3 weeks after the end of chemotherapy, local treat-
ment (surgery and/or radiotherapy) was performed. 
Surgery 
The operative procedure in both groups consisted of a commando
procedure i.e. oropharyngeal composite resection with segmental
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initial volume before chemotherapy whatever the response. In the
same time N0 patients and patients with nodes measuring less than
3 cm underwent modified neck dissection. Patients with nodes
exceeding 3 cm or more underwent homolateral radical neck
dissection. In the chemotherapy group, surgery was performed 2 to
3 weeks after the end of the last chemotherapy cycle. 
Post-operative radiation therapy 
Radiotherapy was delivered by 60Co γ rays in daily fractions of
2 Gy. In patients with free surgical margins, 50 Gy were delivered
over 5 weeks to the tumour site and 50 Gy to the bilateral superior
and inferior cervical areas, with a boost of 15 Gy in case of extra-
capsular spread. In patients with positive surgical margins, 65 Gy
were delivered in 6 1/2 weeks to the tumour site and bilateral
superior cervical areas, and 50 Gy to the inferior cervical areas,
with a boost of 15 Gy in case of extra-capsular spread. 
In all cases the posterior spinal area was treated with 42 Gy
(60Co) completed with 8 Gy by electron therapy and a boost of
15 Gy, in case of extracapsular spread. Radiotherapy was to
begin within 10 weeks after surgery. 
Radiotherapy alone 
Radiotherapy began 2 to 3 weeks after the completion of chemo-
therapy. 70 Gy were delivered in 7 weeks to the tumour and bilat-
eral superior cervical nodes, and 42 Gy to the posterior cervical
field completed with 8 Gy by electron therapy if nodes were not
palpable. At the end of radiotherapy, 5 additional Gy were deliv-
ered to the tumour site, in case of residual tumour. A boost of
23 Gy was delivered to palpable posterior cervical nodes by elec-
tron therapy. 50 Gy were delivered in 5 weeks to the median and
inferior cervical areas, with a boost of 15 Gy to palpable nodes
with an electron beam. 
Endpoints 
Toxicity was evaluated using WHO scale. Response was assessed
by clinical examination at the beginning of each chemotherapy
cycle. 7–10 days after the third cycle of chemotherapy, clinical
examination and a CT scan were performed. Survival was the
primary endpoint. Disease-free survival was a secondary endpoint.
Overall survival was to be calculated as the time from the date of
randomization to either the date of death or to the date of the last
follow-up. Event-free survival was to be calculated as the time
from the date of randomization to the date of the first event which
was documented as a recurrence (local, loco-regional or meta-
static), or a second primary, or death, or to the date of the last
follow-up. 
Statistical analysis 
A total of 760 patients were to be included in the trial, 400 in the
surgery followed by radiotherapy stratum and 360 in the radio-
therapy alone stratum. These sample sizes allowed a 90% chance
of detecting a difference of 10% in the survival rate and 3 analyses
were to be conducted after 18, 36 and 60 months of follow-up 
(α = 5%). 
The analysis was to include all randomized patients and use the
intention-to-treat principle. 
Survival curves used Kaplan–Meier plots, and were to be com-
pared using the log-rank test. The median follow-up time was
computed using the inverse Kaplan–Meier method (Schemper and
Smith, 1996). A marginal hazards Cox model (Wei et al, 1989) has
been used to estimate simultaneously the effects of chemotherapy
on the risk of first local recurrence or head and neck second
primary, first metastasis, first second primary other than head and
neck and death. This model takes into account the correlation
between events in the same patient. 
RESULTS 
This trial was activated in 1986 and closed to patient accrual in
1992. A total of 318 patients were included in the study, 157 in the
induction chemotherapy group and 161 in the no chemotherapy
group. The trial was interrupted after 6 years of accrual, because
the accrual rate had become very low. 
Patient characteristics are presented in Table 1. They were well
balanced and there were no significant differences between the
treatment arms with respect to sex, age, primary site, T, N stage
and performance status. Table 2 gives the TNM distribution by
treatment group. 
Treatment 
Surgery 
Among the 71 patients in the chemotherapy group, and for whom
surgery had been planned, 11 did not undergo surgery: one patient
died of heart failure between chemotherapy cycles and radio-
therapy was preferred for 10 others, 5 as they were considered
good responders and 5 as they refused surgery. Among the 73
patients who were not to receive chemotherapy and for whom
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Table 1 Patient characteristics 
Treatment group 
Characteristic No chemotherapy Chemotherapy 
(161) (157) 
Age: mean (SDa) 54.2 (8.3) 52.4 (8.6) 
Sex: number and % males 149 93% 141 90% 
Primary site 
Tongue 53 33% 54 34% 
Tonsil 79 49% 76 49% 
Velar 15 9% 17 11% 
Other 14 9% 10 6% 
T 
26 4 b 40% 63 40% 
3 82 51% 82 52% 
4 15 9% 12 8% 
N 
0 81 50% 80 51% 
1 46 29% 45 29% 
2 34 21% 32 20% 
Stage 
2 42 26% 40 25% 
3 76 47% 77 49% 
4 43 27% 40 25% 
ECOG performance status 
0 71 44% 72 46% 
1 80 50% 77 49% 
2 10 6% 8 5% 
aSD: Standard deviation. bIncludes one T1 patient included by error.1596 C Domenge et al
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bucco-pharyngectomy had been planned, 2 only had neck dissec-
tion and radiotherapy to the primary and nodes. 
Post-operative radiotherapy 
After chemotherapy and surgery, one patient with negative nodes
and free surgical margins had no further treatment. 
Radiotherapy alone 
7 patients had no radiotherapy: 6 were in the chemotherapy group
(2 deaths including 1 from chemotoxicity, 2 by medical decision, 
1 refusal, and 1 with a hypo-pharyngeal second primary) and 1 in
the control group (death by suicide). 
Chemotherapy 
In the chemotherapy arm, 97% of the patients received at least one
cycle of chemotherapy, and 78% received the 3 planned cycles. 
Toxicity of chemotherapy 
Among the 152 patients who received chemotherapy, 50% experi-
enced toxicity (Table 3). Toxicity was grade 1 or 2 in 32%, grade 3
in 14% and grade 4 in 4%. These toxicities were mostly haemato-
logical (26%), digestive (22%), and mucositis (13%). 
Response after chemotherapy 
56% of patients achieved an objective response, 20% a complete
response and 36% a partial response (> 50%). 
Overall and event-free survival 
The median duration of follow up was 5 years. At the time of the
analysis 165 deaths had occurred, 73 in the chemotherapy group
and 92 in the control group. 6 treatment-related deaths were
observed, 3 per group. 
A total of 40 patients never achieved a complete remission after
treatment, 25 in the control group and 15 in the chemotherapy
group. Event-free survival was considered 0 for these patients.
Table 4 describes the type of first event by treatment group.
Among the patients with death as the first event, half of them died
of intercurrent causes, the cause of death was not available in 35%
but they were free of recurrence and metastasis when last seen, and
16% died of treatment-related toxicity. 
The overall survival curves and event-free survival curves 
are shown in Figures 1 and 2. The difference between the survival
curves, adjusted on the initial therapy (radiotherapy alone or
surgery plus radiotherapy) is statistically significant (P = 0.03) 
for overall survival and in favour of the chemotherapy group
(Table 5). No significant difference was found between the arms 
in event-free survival. Median survival is 5.1 years in the chemo-
therapy group versus 3.3 years in the control group. 
When the results were stratified on local treatment (surgery +
radiotherapy versus radiotherapy alone) no heterogeneity was
demonstrated between strata in the effect of neoadjuvant
chemotherapy on overall survival (Figure 3). 
Table 2 TNM distribution by treatment group 
Treatment group T/N N0 N1 N2 N2a N2b N2c Total 
No chemotherapy 
T 1 00 100 0 1  
T2 42 11 0 5 4 1 63 
T3 34 31 0 9 5 3 82 
T 4 54 013 21 5  
Total 81 46 1 15 12 6 161 
Chemotherapy 
T2 40 12 1 6 4 0 63 
T3 36 29 0 9 4 4 82 
T 4 44 010 31 2  
Total 80 45 1 16 8 7 157 
Table 3 Chemotherapy toxicity, maximum grade observed for each patient 
Type of toxicity
Grade 
I II III IV 
Nausea, vomiting 11 17 4 2 
Leucopenia 8 17 10 2 
Thrombopenia 2 6 3 1 
Mucositis 4 8 5 3 
Cutaneous 1 3 2 1 
Fatigue 6 2 0 1 
Renal 5 1 2 1 
Infection 2 0 1 0 
Table 4 Type of first event by treatment group 
Treatment group 
Type of first event
No chemotherapy Chemotherapy Total 
Loco-regional recurrence 48 39 87 
Metastasis 20 13 33 
Head and neck 2nd primary 8 14 22 
Other second primary 8 11 19 
Death 20 15 35 
Total 104 92 196 Chemotherapy trial in oropharyngeal cancer 1597
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Marginal hazards model 
The results of the marginal hazards model are given in Table 6.
There were no significant effects of chemotherapy on the risk of
first local recurrence or head and neck second primary, on the risk
of first metastasis, or on the risk of first second primary other than
head and neck. As already shown with the logrank test, chemo-
therapy is associated with a significant reduction in the risk of
death. 
DISCUSSION 
This trial shows significantly better overall survival (P = 0.03) in
the neoadjuvant chemotherapy group than in the control group.
The effect of neoadjuvant chemotherapy on event-free survival
was smaller and of borderline significance (P = 0.11). 
The study was terminated after 6 years of accrual, before
reaching the target sample size, because the investigators had lost
interest in the evaluation of neoadjuvant chemotherapy. They were
sufficiently convinced of its efficacy because it allowed organ
preservation and because they believed that it was associated with
longer survival owing to the observation of clinical and patho-
logical responses after chemotherapy, considered predictive of
longer survival. The decision to stop the trial was completely inde-
pendent of the results which were not available at the time. It is
therefore very unlikely that early termination is a cause of bias. 
The chemotherapy effect we observed is consistent with the
overall effect of chemotherapy demonstrated by Pignon et al
(2000) in their meta-analysis, i.e. a 10% reduction in the risk of
death. The effect of neoadjuvant cisplatin plus fluorouracil on
survival in our trial (a hazard ratio for death of 0.71 with a 95% CI
of 0.40–1.02) is in agreement with the significant benefit observed
Table 5 Log-rank tests for survival and disease-free survival, adjusted for initial therapy
(radiotherapy alone or surgery plus radiotherapy) 
Number of deaths 
Chemotherapy Observed Expected O-E Var(O-E) P value 
No 92 78.0 14.0 40.7 0.03 
Yes 73 87.0 –14.0 40.7 
Number of events 
Chemotherapy Observed Expected O-E Var(O-E) P value 
No 104 92.9 11.1 48.7 0.11 
Yes 92 103.1 –11.1 48.7
0
20
40
60
80
100
0 12345678
No chemotherapy
Chemotherapy
Years
Patients at risk
161 137 101 65 48 28 16 7
157 138 105 86 59 33 19 7
Figure 1 Overall survival by treatment group 
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Figure 2 Event-free survival by treatment group 
RT & surgery 27/71
55/88 46/86
73/157
-7.5 24.8
37/73 -6.5 15.9
92/161 -14.1 40 Total
RT alone
Category New Control 0-E Variance (New/Control) (SD)
No. Events/No. Entered Relative Risk Risk Redn
0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25
New better
New effect 2p=0.03 Test for heterogeneity c
2
1 = 0.11 2p=0.74
Control better
26% – 17%
34% – 21%
29% – 13%
Figure 3 Effect of treatment on survival according to loco-regional treatment 1598 C Domenge et al
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with neoadjuvant cisplatin plus fluorouracil (hazard ratio 0.88,
95% CI 0.79–0.97) in the above-mentioned meta-analysis which
includes our trial. Pignon et al (2000) found that the effect of a
neoadjuvant regimen combining cisplatin and fluorouracil was
significantly different (P = 0.05) from that of the other neoadju-
vant regimens. These other regimens either did not contain
cisplatin or were early studies of suboptimal cisplatin doses. 
In conclusion, we observed better survival with induction
chemotherapy combining cisplatin and fluorouracil than with no
chemotherapy, in patients with oropharyngeal carcinoma. This is
consistent with the results of Dr Pignon’s meta-analysis. However,
these results are not convincing enough to establish neoadjuvant
chemotherapy with cisplatin and fluorouracil as a standard
treatment, and new drugs will have to be compared to no
chemotherapy in large randomized trials. 
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